Bioheart owns or holds licenses or hold sub-licenses to an intellectual property portfolio consisting of approximately 19 patents and 19 patent applications in the United States, and approximately 12 patents and 57 patent applications in foreign countries, all for use in the field of heart muscle regeneration. Our intellectual property strategy emphasizes method, product and device patents. We rely primarily on one U.S. patent for MyoCell, or the Primary MyoCell Patent; one U.S. patent for MyoCath, or the Primary MyoCath Patent; and a number of patents for MyoCath II. We rely on three pending U.S. patent applications and corresponding foreign patent applications for MyoCell SDF-1 and three U.S. patents for BioPace. For most of our other product candidates, we rely on one primary patent, multiple patents in combination and/or proprietary processes. The following provides a description of our key patents and pending applications and is not intended to represent an assessment of claims, limitations or scope.

Patent	Subject Matter	Related Product(s)	Expiration Date Assuming No Patent Extension
US5,130,141	Compositions for and methods of treating muscle degeneration and weakness	MyoCell; MyoCell SDF-1	July 14, 2009
US5,972,013	Direct Pericardial Access Device with Deflecting Mechanism and Method	MyoCath; MyoCathII	Sep. 19, 2017
US6,241,710	Hypodermic Needle with Weeping Tip and Method of Use	MyoCath II	Dec. 20, 2019
US6,547,769	Catheter Apparatus with Weeping Tip and Method of Use	MyoCath II	Dec. 20, 2019
US6,855,132	Apparatus with Weeping Tip and Method of Use	MyoCath II	Dec. 20, 2019 (with 101 day adjustment: Mar. 30, 2020)
US6,949,087	Apparatus with Weeping Tip and Method of Us	MyoCath II	Dec. 20, 2019